share_log

Expert Outlook: Integra Lifesciences Through The Eyes Of 8 Analysts

Benzinga ·  Aug 23 00:00

Integra Lifesciences (NASDAQ:IART) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings01313
Last 30D00001
1M Ago01102
2M Ago00210
3M Ago00000

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $26.88, a high estimate of $35.00, and a low estimate of $20.00. Experiencing a 6.86% decline, the current average is now lower than the previous average price target of $28.86.

1724342454_0.png

Investigating Analyst Ratings: An Elaborate Study

The analysis of recent...

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment